Onesource Specialty Pharma Ltd.
ONESOURCEHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
5 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 5 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20250512 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250812 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251118 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260519 | 2026-03-31 | yes | |
| TRANSCRIPT | 20260731 | 2026-06-30 | yes |
ONESOURCE
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
No split, bonus or consolidation is on record for this company inside the period this price series covers, so the closes need no adjustment.
| Last close | 1,594.60 |
| 52-week range | 1114.0 – 1889.8 |
| Return 1M | 5.18% |
| Return 3M | 2.48% |
| Return 1Y | -9.03% |
| Return 3Y | not reported for this period |
| Return 5Y | not reported for this period |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 449.00 |
| Other income | 4.00 |
| Total income | 453.00 |
| Cost of materials consumed | 141.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | 1.00 |
| Employee benefit expense | 69.00 |
| Finance costs | 31.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.30 | 0.00 |
| institutions foreign | 0.19 | 0.02 |
| institutions domestic | 0.23 | 0.03 |
| mutual funds | 0.13 | 0.03 |
| public | 0.70 | 0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 5 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 68.00 | 393.00 | 426.00 | 327.00 | 376.00 | 290.00 | 428.00 | 449.00 |
| Other income | 1.00 | 5.00 | 3.00 | 5.00 | 3.00 | 5.00 | 2.00 | 4.00 |
| Total income | 69.00 | 398.00 | 429.00 | 333.00 | 379.00 | 295.00 | 430.00 | 453.00 |
| Cost of materials consumed | 12.00 | 93.00 | 91.00 | 83.00 | 124.00 | 88.00 | 145.00 | 141.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | -8.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | 0.00 | 9.00 | 28.00 | 10.00 | -10.00 | 7.00 | 2.00 | 1.00 |
| Employee benefit expense | 23.00 | 57.00 | 51.00 | 58.00 | 63.00 | 64.00 | 63.00 | 69.00 |
| Finance costs | 21.00 | 46.00 | 33.00 | 27.00 | 34.00 | 38.00 | 23.00 | 31.00 |
| Depreciation and amortisation | 19.00 | 69.00 | 68.00 | 68.00 | 70.00 | 70.00 | 72.00 | 72.00 |
| Other expenses | 33.00 | 90.00 | 81.00 | 87.00 | 93.00 | 114.00 | 127.00 | 115.00 |
| Total expenses | 108.00 | 364.00 | 345.00 | 334.00 | 373.00 | 381.00 | 431.00 | 428.00 |
| Profit before exceptional items and tax | -39.00 | 34.00 | 84.00 | -2.00 | 6.00 | -86.00 | -0.00 | 25.00 |
| Exceptional items | 0.00 | -101.00 | 0.00 | -3.00 | 0.00 | -7.00 | 0.00 | -4.00 |
| Profit before tax | -39.00 | -67.00 | 84.00 | -4.00 | 6.00 | -93.00 | -0.00 | 20.00 |
| Current tax | 0.00 | 6.00 | -11.00 | 0.00 | 1.00 | 1.00 | 0.00 | 0.00 |
| Deferred tax | 0.00 | -4.00 | -5.00 | -4.00 | -6.00 | -5.00 | -5.00 | -5.00 |
| Tax expense | 0.00 | 2.00 | -15.00 | -4.00 | -5.00 | -4.00 | -5.00 | -5.00 |
| Profit for the period | -39.00 | -69.00 | 98.00 | -0.00 | 10.00 | -89.00 | 5.00 | 25.00 |
| Profit attributable to owners | 0.00 | 0.00 | — | — | — | -89.00 | 5.00 | 0.00 |
| Profit attributable to non-controlling interests | 0.00 | -2.00 | — | — | — | 0.00 | 0.00 | 0.00 |
| Other comprehensive income | 0.00 | 0.00 | 2.00 | 3.00 | 6.00 | -3.00 | 11.00 | 4.00 |
| Total comprehensive income | -39.00 | -69.00 | 100.00 | 3.00 | 16.00 | -92.00 | 15.00 | 29.00 |
| Earnings per share, basic | -18.82 | -6.31 | 8.61 | -0.02 | 0.92 | -7.74 | 0.40 | 2.18 |
| Earnings per share, diluted | -18.82 | -6.31 | 8.59 | -0.02 | 0.91 | -7.74 | 0.40 | 2.18 |
Annual results, as filed
| Line | 2025-03-31 | 2026-03-31 |
|---|---|---|
| Revenue from operations | 1,445.00 | 1,422.00 |
| Other income | 17.00 | 15.00 |
| Total income | 1,462.00 | 1,437.00 |
| Cost of materials consumed | 328.00 | 437.00 |
| Purchases of stock-in-trade | 30.00 | 0.00 |
| Changes in inventories | 77.00 | 8.00 |
| Employee benefit expense | 215.00 | 242.00 |
| Finance costs | 166.00 | 122.00 |
| Depreciation and amortisation | 274.00 | 279.00 |
| Other expenses | 328.00 | 430.00 |
| Total expenses | 1,419.00 | 1,519.00 |
| Profit before exceptional items and tax | 44.00 | -82.00 |
| Exceptional items | -111.00 | -10.00 |
| Profit before tax | -67.00 | -92.00 |
| Current tax | 12.00 | 2.00 |
| Deferred tax | -62.00 | -20.00 |
| Tax expense | -50.00 | -18.00 |
| Profit for the period | -18.00 | -74.00 |
| Profit attributable to owners | — | -74.00 |
| Profit attributable to non-controlling interests | — | 0.00 |
| Other comprehensive income | -3.00 | 16.00 |
| Total comprehensive income | -21.00 | -58.00 |
| Earnings per share, basic | -1.63 | -6.44 |
| Earnings per share, diluted | -1.63 | -6.44 |
Balance sheet, as filed
| Line | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|
| Total assets | 1,283.00 | 7,550.00 | 8,013.00 | 8,210.00 |
| Non-current assets | 1,125.00 | 6,464.00 | 6,659.00 | 6,784.00 |
| Current assets | 158.00 | 1,086.00 | 1,355.00 | 1,426.00 |
| Property, plant and equipment | 654.00 | 897.00 | 921.00 | 926.00 |
| Capital work-in-progress | 43.00 | 60.00 | 173.00 | 314.00 |
| Goodwill | 0.00 | 3,828.00 | 3,828.00 | 3,828.00 |
| Other intangible assets | 173.00 | 1,393.00 | 1,340.00 | 1,264.00 |
| Inventories | 14.00 | 158.00 | 325.00 | 439.00 |
| Trade receivables | 63.00 | 417.00 | 664.00 | 690.00 |
| Cash and cash equivalents | 9.00 | 156.00 | 104.00 | 36.00 |
| Total equity and liabilities | 1,283.00 | 7,550.00 | 8,013.00 | 8,210.00 |
| Equity | 405.00 | 5,881.00 | 5,904.00 | 5,831.00 |
| Equity share capital | 4.00 | 11.00 | 11.00 | 11.00 |
| Other equity | 401.00 | 5,869.00 | 5,893.00 | 5,820.00 |
| Total liabilities | 878.00 | 1,670.00 | 2,109.00 | 2,379.00 |
| Non-current liabilities | 464.00 | 556.00 | 778.00 | 937.00 |
| Current liabilities | 414.00 | 1,114.00 | 1,331.00 | 1,442.00 |
| Borrowings, non-current | 453.00 | 219.00 | 393.00 | 564.00 |
| Borrowings, current | 150.00 | 552.00 | 673.00 | 713.00 |
| Trade payables | 54.00 | 176.00 | 284.00 | 375.00 |
Cash flow, as filed
| Line | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|
| Net cash from operating activities | -81.00 | -22.00 | -40.00 | 9.00 |
| Net cash from investing activities | 0.00 | -201.00 | -251.00 | -495.00 |
| Net cash from financing activities | 85.00 | 1,987.00 | 231.00 | 359.00 |
| Purchase of property, plant and equipment | 30.00 | 0.00 | 329.00 | 569.00 |
| Net increase in cash | 5.00 | 1,765.00 | -59.00 | -127.00 |
| con:CFO.BEFORE_TAX | -80.00 | -29.00 | -35.00 | 17.00 |
| con:INTEREST_RECEIVED.OPERATING | -1.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 0.00 | -7.00 | 5.00 | 9.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | -124.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2024-12-31 | 2025-01-24 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 37.77 | 37.77 | 34.25 | 29.79 | 0.30 | 0.30 | 0.30 | 0.30 |
| Domestic institutions | 12.56 | 12.56 | 18.04 | 18.10 | 0.18 | 0.19 | 0.21 | 0.23 |
| Mutual funds | 4.62 | — | 8.32 | 9.06 | 0.09 | 0.09 | 0.10 | 0.13 |
| Insurance companies | 2.47 | 2.47 | 2.78 | 2.19 | 0.02 | 0.03 | 0.03 | 0.03 |
| Foreign institutions | 17.44 | 17.44 | 18.54 | 18.69 | 0.19 | 0.19 | 0.17 | 0.19 |
| Government | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 62.23 | 62.23 | 65.75 | 70.21 | 0.70 | 0.70 | 0.70 | 0.70 |
| Non-institutional | 32.23 | 32.23 | 29.17 | 33.42 | 0.32 | 0.32 | 0.31 | 0.27 |
| Shares outstanding | 114436021 | 114436021 | 114436021 | 114466021 | 114525216 | 114585136 | 114621201 | 114645801 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-07-31 | Q1FY27 | Read the call | |
| 2026-05-19 | Q4FY26 | PHARMA LIMITED | Read the call |
| 2025-11-18 | Q2FY26 | LIMITED, PHARMA LIMITED | Read the call |
| 2025-08-12 | Q1FY26 | ONESOURCE SPECIALTY PHARMA LIMITED, PHARMA LIMITED | Read the call |
| 2025-05-12 | Q4FY25 | PHARMA LIMITED | Read the call |
What they said about it, quarter by quarter
| Topic | Q1FY26 | Q1FY27 | Q2FY26 | Q4FY25 | Q4FY26 |
|---|---|---|---|---|---|
| Capex | And while this is still within the overall $100 million capex plan, which we have announced earlier, but the entire implementation will be completed a… | Last question, what is the kind of capex that we are looking for this year and the next year, including all the capacity expansions that we are talkin… | This increase is largely demonstrated in the ongoing capital expansion that we are doing, which we are actually accelerating in terms of our capex inv… | Some customers have participated in our capex program. | What we are also doing from a balance sheet standpoint is there is capacity build- out, and that's the increase that you may be seeing in the capex si… |
| Capital allocation | You give a lot of information regarding the acquisition of the two plants. | And there is a significant amount of interest in this considering, some of the largest players in Europe have had various challenges, either because o… | And in fact, even our recently announced acquisition or proposed acquisition in Poland and in Brookes, they have also performed well. | — | — |
| Debt and cash | — | — | As of September 30th, moving on to our working capital, we had a working capital of INR 5936 million. | — | So as I mentioned earlier to Rupesh, I think what you're seeing is an increased elevated level of working capital. |
| Demand | I think what we are saying is that we believe that the demand is significantly greater than what we had anticipated in terms of timing. | So, thanks to all these, we are able to actually pull demand into this quarter, therefore, which is what the timeline which Dr. Reddy's has shared pub… | Coming specifically to our current business areas, our drug device combination, Arun already mentioned that, the order book here remains really solid. | So, you know, we see these markets right now, what the numbers which IQVIA shows are really, you know, not reflective of the true demand. | It is paid for by the customers already, just for you to know, because our benefit to our customers, Rupesh, is the fact that we are able to combine, … |
| Guidance | August 05, 2025 We reinforce our earlier guidance on the financial metrics and expect to be 1.5x EBITDA on our debt metric. | It will be a strong driver of our growth, in the foreseeable FY28 guidance, but also beyond that period. | And just a final one from my end, on the guidance revision. | Arun, just taking off from the comment that you made on the F '26 guidance, just to be clear, I think what we should be looking at may be F '25-'6 whi… | It is for supporting our guidance of $400 million revenue. |
| Margin | In fact, EBITDA growing quite robustly at 37% versus last year and the EBITDA margin being up 500 basis points. | And also, any update on the margin improvement program we had for Steri- Science? | In fact, the EBITDA margin expanded by more than 500 basis points, so all in right direction. | — | And secondly, the non-CDMO business or the injectable plus capsule business, what kind of EBITDA margins that we do? |
| People | — | Neeraj, just trying to assess; line two utilization. | How should we think about, like, the maximum capacity utilization that we can do? | So, I mean, you know, how should we look at the utilization part considering, you know, you're talking about a significant capacity to be added in, yo… | And if you can also give some sense on by when do you see reasonable utilization of these capacities in your plans? |
| Pricing | We believe that an improved price point, and there is obviously no worse we can't specifically comment on a company, but I think it's also to do with … | — | — | OneSource Specialty Pharma Limited May 06, 2025 But I think a combination of pill burden and pricing and availability of these products in the markets… | — |
| Revenue growth | And as a part of this journey and the transition, our Q1 performance has been in line with our expectations, where we have delivered growth both on to… | — | We had quite healthy revenue growth, supported by a number of MSA executions, and even the EBITDA saw a very robust growth of 37%. | — | — |